- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01819051
Pilot Study to Evaluate Plasma Treatment of Onychomycosis
September 12, 2017 updated by: Moe Medical Devices
A Single Center, Pilot Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of the Plasma Treatment System in Treating Onychomycosis
The purpose of this study is to evaluate the safety of treating human toenails with atmospheric plasma (MOE Antimicrobial Plasma Treatment System) and get an initial evaluation of the efficacy of this treatment for toenail fungus (onychomycosis).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
15
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Weill Cornell Medical College
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject must be between 18 and 75 years of age inclusive, of either sex, and of any race;
- Subject must have distal subungual infection that affects approximately 25% to 50% of at least one great toenail, both clinically and mycologically diagnosed;
- Subject must have at least 2 mm of the proximal end of the target toenail free of infection;
- Subject must have a target toenail that is assessed as capable of growing approximately 1 mm/month, (e.g., the subject needs to report cutting his or her toenails at least once per month);
- Subject must be willing to give written informed consent and able to adhere to procedures and visit schedules;
- Woman of childbearing potential who is currently sexually active must agree to use a medically accepted method of contraception while receiving protocol-specified medication and for 30 days after stopping the medication. Methods include condoms (male or female) with or without a spermicidal agent, diaphragm or cervical cap with spermicide, medically prescribed intrauterine device, oral or systemic hormonal contraceptive (plus an additional reliable barrier method), and surgical sterilization (e.g., hysterectomy or tubal ligation).
- Woman of child-bearing potential who is not currently sexually active must agree to use a medically accepted method of contraception should she become sexually active while participating in the study.
- Woman of childbearing potential must have a negative serum pregnancy test within 72 hours prior to start of study drug.
Exclusion Criteria:
- Subject with one or more of the following conditions on the target toenail:
- proximal subungual onychomycosis,
- white superficial onychomycosis,
- dermatophytoma or "yellow spike/streak",
- exclusively lateral disease,
- inability to become normal in the opinion of the investigator.
- Subject with psoriasis, severe moccasin-type tinea pedis requiring treatment, symptomatic interdigital tinea pedis, lichen planus, or other abnormalities that could result in a clinically abnormal nail;
- Subject with peripheral vascular disease or peripheral circulatory impairment;
- Subject with history of uncontrolled diabetes mellitus;
- Subject with known chronic or active liver disease;
- Subject with any known immunodeficiency;
- Any pacemakers, or any metallic implants or prostheses in the vicinity of the treatment site (such as ankle, foot, etc.).
- Subject with any clinically significant condition or situation, other than the condition being studied that, in the opinion of the investigator, would interfere with study evaluations or optimal participation in the study;
- Subject who has received systemic antifungal therapy within 6 months or topical antifungal therapy applied to the foot or toenails within 1 month of study entry;
- Subject who has received radiation therapy, chemotherapy, and/or immunosuppressive drugs within 6 months of study, and/or oral corticosteroids for >1 month within the 6 months of study (exception: inhaled steroids);
- Subject known to have received treatment with investigational drugs within 30 days prior to enrollment into this study;
- Subject who is unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function
- Subjects who may be unreliable for the study including subjects who engage in excessive alcohol intake or drug abuse (no testing required), or subjects who are unable to return for scheduled follow-up visits
- Woman who is breastfeeding, pregnant, or intends to become pregnant;
- Subject who is part of the staff personnel directly involved with this study;
- Subject who is a family member of the investigational study staff.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Plasma
Apply plasma to great toenail for up to 20 minutes, 1X/week for 3 weeks
|
Plasma applied to great toenail 1X/week for three weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in number of reported adverse events
Time Frame: Change from Baseline to 6 months post-treatment
|
Change from Baseline to 6 months post-treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2013
Primary Completion (ACTUAL)
March 1, 2015
Study Completion (ACTUAL)
March 1, 2015
Study Registration Dates
First Submitted
March 22, 2013
First Submitted That Met QC Criteria
March 26, 2013
First Posted (ESTIMATE)
March 27, 2013
Study Record Updates
Last Update Posted (ACTUAL)
September 14, 2017
Last Update Submitted That Met QC Criteria
September 12, 2017
Last Verified
September 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MOE - 131
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Onychomycosis
-
Vésale HospitalJanssen-Cilag Ltd.CompletedPrevalence of Onychomycosis | Diabetic Neuropathic Patients | Diagnostic of Onychomycosis | Patients Clinically Suspected of Onychomycosis | Reliability of the Diagnosis of OnychomycosisBelgium
-
University of Alabama at BirminghamDUSA Pharmaceuticals, Inc.CompletedToenail Onychomycosis | Distal and Lateral Subungual Toenail OnychomycosisUnited States
-
DeviceFarm, Inc.Symbio, LLC; Center for Dermatology Clinical Research, Inc.CompletedOnychomycosis Due to Trichophyton Rubrum | Onychomycosis Due to Trichophyton MentagrophytesUnited States
-
Janssen Korea, Ltd., KoreaCompleted
-
Cairo UniversityRecruiting
-
Mediprobe Research Inc.Emblation LimitedRecruiting
-
Oystershell NVCompletedOnychomycosis of ToenailTunisia
-
Erchonia CorporationWithdrawnOnychomycosis of ToenailUnited States
-
William N HandelmanUnknown
-
DeviceFarm, Inc.CompletedOnychomycosis | Onychomycosis of ToenailUnited States
Clinical Trials on MOE Antimicrobial Plasma Treatment System
-
Moe Medical DevicesTerminated
-
Moe Medical DevicesUnknown
-
DeviceFarm, Inc.CompletedOnychomycosis | Onychomycosis of ToenailUnited States
-
DeviceFarm, Inc.Symbio, LLC; Center for Dermatology Clinical Research, Inc.CompletedOnychomycosis Due to Trichophyton Rubrum | Onychomycosis Due to Trichophyton MentagrophytesUnited States
-
Fundación Pública Andaluza para la gestión de la...Completed
-
National Institute of Health Research and Development...Eijkman Institute for Molecular Biology; Indonesian Red CrossRecruiting
-
Clinical Research Management, Inc.UnknownEbola Virus DiseaseLiberia
-
Charite University, Berlin, GermanyUnknownSurgical Procedure, Unspecified | Vertebral Osteomyelitis | SpondylodiscitisGermany
-
National Blood Center Foundation, HemolifeUnknownInfections, CoronavirusColombia
-
Nanova, IncNational Institute of Dental and Craniofacial Research (NIDCR)Completed